

available at www.sciencedirect.comjournal homepage: www.elsevier.com/locate/biochempharm

Deoxyelephantopin inhibits cancer cell proliferation and functions as a selective partial agonist against PPAR γ

Gang Zou^{a,1}, Zhenting Gao^{a,1}, Jidong Wang^b, Yu Zhang^b, Hong Ding^b, Jin Huang^a, Lili Chen^b, Yuewei Guo^{b,**}, Hualiang Jiang^{a,b}, Xu Shen^{a,b,*}

^a School of Pharmacy, East China University of Science and Technology, Shanghai 200237, China

^b Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 210203, China

ARTICLE INFO

Article history:

Received 12 October 2007

Accepted 27 November 2007

Keywords:

Deoxyelephantopin

PPAR γ

Partial agonist

Surface plasmon resonance

Molecular docking

ABSTRACT

Deoxyelephantopin (ESD) was reported to potentiate apoptosis, inhibit invasion and abolish osteoclastogenesis but no target protein was disclosed. Here, we discovered that ESD could significantly inhibit the proliferation of different cancer cells and induce apoptosis and cell cycle arrest at G₂/M phase in HeLa cell. Moreover, biochemical and biophysical assays revealed that ESD acted as a specific partial agonist against PPAR γ . Molecular docking with site-directed mutagenesis analyses indicated that ESD functioned as a partial agonist of PPAR γ by adopting a distinct binding mode to PPAR γ compared with rosiglitazone. The PPAR γ knockdown results indicated that the inhibition of ESD against the cancer cell proliferation is more possibly through PPAR γ -independent pathway and our findings might supply potent binding features for ESD/PPAR γ interaction at atomic level, and shed light on the potential acting target information for this natural compound.

© 2007 Elsevier Inc. All rights reserved.

1. Introduction

It has been known that the nuclear hormone receptor peroxisome proliferator-activated receptor- γ (PPAR γ) is related not only to metabolic disorders but also to inflammation, atherosclerosis, immunomodulation and cancer [1]. The four somatic PPAR γ mutations found in sporadic colon cancers have suggested that PPAR γ might act as a tumor suppressor [2] as further confirmed by the fact that synthetic PPAR γ full

agonists, thiazolidinediones (TZDs) (e.g. troglitazone, Fig. 1) were able to induce cell differentiation and apoptosis or inhibit cell proliferation both *in vitro* (e.g. human liposarcoma [3], colon cancer [4] and malignant breast epithelial cells [5,6]) and *in vivo* (e.g. female triple-immunodeficient BNX nude mice (Harlan–Sprague–Dawley) [5,6]).

To date, a number of reports have indicated that the therapeutic benefits of PPAR γ agonists might go far beyond their uses in diabetes, and evidence has emerged of their uses

* Corresponding author at: Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 210203, China. Tel.: +86 21 50806918; fax: +86 21 50806918.

** Corresponding author.

E-mail addresses: ywguo@mail.shcnc.ac.cn (Y. Guo), xshen@mail.shcnc.ac.cn (X. Shen).

¹ They contributed equally.

Abbreviations: ESD, deoxyelephantopin; PPAR γ , peroxisome proliferator-activated receptor- γ ; TZDs, thiazolidinediones; NF- κ B, nuclear factor- κ B; LBD, ligand-binding domain; AF-2, ligand-dependent activation domain; SRC-1, steroid receptor coactivator-1; CBP, cAMP-response element-binding protein (CREB)-binding protein; IPTG, isopropyl- β -D-thiogalactoside; IKK, I κ B α kinase; AP-1, activator protein-1; STAT, signal transduction and activator of transcription; HDAC3, (NCoR)-histone deacetylase-3.

0006-2952/\$ – see front matter © 2007 Elsevier Inc. All rights reserved.

doi:10.1016/j.bcp.2007.11.021




Fig. 1 – Structures of deoxyelephantopin (ESD) and other known PPAR γ agonists with anti-tumor activities.

in inflammatory and cancer diseases. Apart from the above-mentioned TZDs, some other types of PPAR γ ligands with anti-tumor activities were also discovered (Fig. 1). For example, CDDO induced growth arrest and apoptosis of breast cancer cell by acting as a partial agonist against PPAR γ [7]; GW7845, a potent PPAR γ agonist, significantly reduced the incidence, number, and weight of tumors when fed to rats after carcinogen administration [8]; MCC-555, a unique partial agonist of PPAR γ as an antidiabetic drug, inhibited the growth of prostate cancer cells both *in vitro* and *in vivo* [9,10]; GW1929, one of the PPAR γ agonists, could stimulate the differentiation of human neuroblastoma cells [11]. Additionally, several PPAR γ antagonists, e.g. GW9662 and T0070907, were also reported to strongly inhibit the growth of squamous cell carcinomas presumably by blocking the PPAR γ pathway [12,13]. All these results have thereby offered an exciting prospect of using PPAR γ ligands for tumor therapy.

The natural product deoxyelephantopin (ESD, Fig. 1) was recently reported to repress nuclear factor- κ B (NF- κ B) activation, but its direct target was not disclosed [14]. Here, we discovered that ESD functioned as a partial agonist of PPAR γ and could significantly inhibit the proliferation of different cancer cells and caused cell cycle arrest at G2/M phase.

2. Materials and methods

2.1. Reagents

All solvents and reagents were purchased commercially and were used without further purifications. The affinity columns and lower molecular weight (LMW) marker were purchased from Amersham Pharmacia Biotech, isopropyl β -D-thiogalactopyranoside (IPTG) was purchased from Promega. SRB and PI were purchased from Sigma Chemical Co. Dulbecco's modified Eagle's medium (DMEM), RPMI1640 and MEM medium were

from GibcoBRL, and fetal bovine serum (FBS) from HyClone. The anti-PARP antibody was purchased from Beyotime Co., anti-PPAR γ antibody was from calbiochem Co., and caspase 3 and caspase 9 antibody were from Santa Cruz Biotechnology, Inc. Lipofectamine 2000 was purchased from Invitrogen. The QuikChange II site-directed mutagenesis kit was from Stratagene.

2.2. Plasmids

The PPAR α -LBD and PPAR δ -LBD were amplified by PCR from pSG-hPPAR α (provided by Dr. X. Lu, Shenzhen Chipscreen Biosciences Ltd.) and pAdTrack-PPAR δ (provided by Dr. B. Vogelstein, Howard Hughes Medical Institute, US) respectively, and then subcloned into vector pET15b to express the His-tagged fusion proteins. The pSuperbasic-siPPAR γ was constructed by inserting the coding sequence of siRNA into the pSuperbasic with BglII-HindIII sites. The sequences of the small interfering RNA (siRNA) against the PPAR γ message was 5'-GCCCTTCACTACTGTTGAC-3' [15]. The plasmid pET15b-hPPAR γ -LBD was kindly donated by Dr. J. Uppenberg, Department of Structural Chemistry, Pharmacia and Upjohn, Sweden, pcDNA3.1-hPPAR γ was a gift from Dr. X. Gao (Chengdu Institute of Biology, CAS, China), and the reporter gene pSV-PPRE-Luc was kindly provided by Dr. Ronald M. Evans (The Salk Institute for Biological Studies, La Jolla, CA, USA). The Gal4-PPAR γ -LBD expression plasmid and the UAS-E1b-TATA-Luc reporter were generously donated from Prof. J. L. Jameson, Department of Medicine, Northwestern Memorial Hospital.

2.3. Protein expression

Expression and purification of the PPAR γ -LBD, PPAR α -LBD and PPAR δ -LBD proteins were performed according to the published methods [16]. The mutant proteins PPAR γ -LBD (S342G)

and PPAR γ -LBD (G284A) were purified by renaturing inclusion bodies based on the published approach [17]. The correct refolding of the mutant proteins was confirmed by circular dichroic spectra (Supplementary Fig. S1).

The proteins were concentrated with a 10-kDa cut-off membrane (Amicon) at 4 °C, and protein concentration was measured by the standard Bradford method.

2.4. Site-directed mutagenesis

Point mutants were introduced into pET15b-hPPAR γ -LBD by PCR-based mutagenesis strategy according to the instruction manual (www.Stratagene.com) with the following mutagenic forward primers (residues underlined represent the mutated codon): S342G, 5'-GATGGGGTTCTCATAGGCGAGGGCCAAG-GCTTC-3'; G284A, 5'-CGGCATCTTTCAGGCCTGCCAGTTTC-GCTC-3'. All the mutations were verified by sequencing.

2.5. Ligand-binding assay

The binding of the related compounds towards PPAR γ -LBD, PPAR α -LBD, PPAR δ -LBD, PPAR γ -LBD (S342G) and PPAR γ -LBD (G284A) proteins was investigated by use of SPR technology-based Biacore 3000 instrument. During the experiment, the relevant proteins were dissolved in coupling buffer (15 μ g ml⁻¹, in 10 mM sodium acetate, pH 5.0) and immobilized on a CM5 sensor chip with *N*-hydroxysuccinimide (NHS), *N*-ethyl-*N'*-(3-dimethylaminopropyl) carbodiimide (EDC) according to the standard amine-coupling procedure. The baseline was equilibrated with a continuous flow of running buffer (10 mM HEPES, 150 mM NaCl, 3 mM EDTA, and 0.005% (v/v) surfactant P20) through the chip for 1–2 h. Different concentrations of related compounds were injected into the channels at a flow rate of 30 μ l min⁻¹ for 60 s, followed by disassociation for 120 s. BIAevaluation software version 3.1 (Biacore) and the 1:1 Langmuir binding fitting model were used to determine the equilibrium dissociation constant (K_D) of ESD (or rosiglitazone) binding to the proteins.

2.6. Molecular modeling

The 3D structure of ESD was constructed by the online demonstration of Corina (http://www.mol-net.com/online_demos/corina_demo.html). The 3D model of PPAR γ -LBD was retrieved from the Brookhaven Protein Data Bank (PDB) (<http://www.rcsb.org/pdb/>) (PDB ID 2F4B) [18]. AutoDock Tools (<http://autodock.scripps.edu/resources/adt>) was used to add hydrogen and assign partial charges to both protein and ligand. AutoDock 3.0.5 [19] was employed for the docking of ESD to PPAR γ -LBD. All the molecular modeling and docking simulations were performed on a Silicon Graphics Origin3800 (with 128 CPUs).

2.7. Transient transfection assay

Transactivation assay for the full-length PPAR γ was performed as previously described [20]. Cells were transiently transfected with expression vectors pSV-PPRE-Luc (0.3 μ g), pCDNA3.1-PPAR γ (0.2 μ g), pCDNA3.1-RXR α (0.2 μ g) and pRL-SV40 as internal control indicated by Dual-Luciferase Reporter

Assay System (Promega). After transfection for 24 h, cells were placed in phenol red-free Dulbecco's modified Eagle's medium with increasing concentrations of ESD or certain concentration of rosiglitazone containing different concentrations of ESD. After incubation with the above compound for another 24 h, cells were lysed and luciferase activity was determined as the -fold activation relative to the untreated cells after normalization with Renilla luciferase values.

A fusion protein containing the yeast Gal4 DNA-binding domain linked to the ligand-binding domain of PPAR γ was also used in transfection experiments with reporter construct UAS-E1b-TATA-Luc as described [21]. All transfections were performed in triplicate and results were expressed as mean \pm S.D. Statistical analysis was performed using Student's *t*-test, with *p* < 0.05 considered statistically significant.

2.8. Sulphorhodamine B assay for cell proliferation

The quantitative sulphorhodamine B (SRB) colorimetric assay [22] was used to determine the anti-proliferation activity of ESD against HGC, A549, and HeLa cells. Cells were seeded into a 96-well plate with 5000 cells per well and incubated at 37 °C for 24 h. The cells were treated with increasing concentrations of ESD for another 72 h and then fixed with 10% trichloroacetic acid for 1 h at 4 °C, followed by air-drying and staining for 20 min at room temperature with 4 mg/ml SRB solution. After that, cells were washed with 1% acetic acid for 5 times and dissolved with 150 μ l of 10 mM unbuffered Tris base. Cell viability was measured by the optical density at 515 nm (Benchmark PlusTM microplate spectrophotometer) and calculated from the data of three wells, the values were obtained from three independent experiments. The wells with or without drugs were used as positive or negative controls.

2.9. RNA interference assay

HGC cells were seeded in 24-well plates and incubated overnight to allow cells to attach to the plate. Transfection was performed according to the manufacturer (www.invitrogen.com). 0.8 μ g PPAR γ siRNA or the control vector pSuper-basic was transiently transfected into the cells with Lipofectamine 2000 (1 μ l per well). Six hours after transfection, the medium was replaced with growth medium containing with serum and the cells were cultured at 37 °C in a CO₂ incubator for another 18 h. ESD (10 μ M) was then added and incubated for 24 h. The cell numbers were measured by SRB assay as indicated in the above method.

2.10. Cell cycle and apoptosis analysis

HeLa cells (6 \times 10⁴ cells/well) were seeded in six-well plates and incubated overnight to allow cells to attach to the plate. After cells incubated with increasing concentrations of ESD for 24 h, the adherent cells were detached with trypsin and the floating cells were then collected by centrifugation at 600 g. The cells were further washed twice with PBS and fixed in 75% ethanol at 4 °C, and collected by centrifugation. Cells were resuspended with 500 μ l PBS containing 100 mg/ml RNase A and incubated for 30 min at 37 °C, followed by filtration and staining with 0.05 mg/ml propidium iodide (PI) for 1 h. The

suspensions were then analyzed by Becton Dickinson FACS-can BD Biosciences, San Jose, CA. The percentage of cells in the G₀/G₁, S and G₂/M phases of cell cycle was determined by their DNA contents and presented as fold of control. Apoptosis was measured by PARP cleavage assay and caspase activation based investigation, which was blotted against ESD-treated cells with anti-PARP, anti-caspase 3 and anti-caspase 9 antibodies based on Western blot analysis.

2.11. Statistical analysis

The data were presented as mean \pm S.D. for at least three separate determinations for each group. Differences between groups were examined for statistical significance using Student's t-test. $p < 0.05$ was used to indicate a statistically significant difference.

3. Results

3.1. ESD is a selective PPAR γ ligand as evaluated by SPR assay

Since PPAR γ ligands, e.g. PPAR γ agonists, partial agonists and antagonists, were confirmed to bind to the ligand-binding domain of PPAR γ *in vitro*, it is essential to investigate the

binding of ESD against PPAR γ , which is the prerequisite for determining the agonistic or antagonistic feature of ESD towards PPAR γ . Here, we used SPR technology based Biacore 3000 biosensor to quantitatively investigate the ESD binding to PPAR γ . The equilibrium dissociation constant (K_D) for evaluation of PPAR γ binding to ESD or rosiglitazone (as a positive control) was obtained by fitting the sensorgram with a 1:1 (Langmuir) binding fit model. As shown in Fig. 2B, ESD showed high binding affinity against PPAR γ -LBD ($K_D = 3.4 \mu\text{M}$), similar to that for rosiglitazone ($K_D = 2.2 \mu\text{M}$, Fig. 2A). Moreover, to further inspect the potential binding specificity of ESD against PPAR γ , we also examined its binding to PPAR α -LBD and PPAR δ -LBD. By using GW14643 (PPAR α agonist) and benzafibrate (PPAR δ agonist) as positive controls (Supplementary Fig. S2A and B), the SPR results clearly indicated that ESD exhibited no binding affinity against PPAR α -LBD and PPAR δ -LBD (Fig. 2C and D), suggesting that ESD might be a selective ligand of PPAR γ .

3.2. ESD increases PPAR γ transactivation

In the determination of the ESD activation against PPAR γ in cultured cells, transactivation assay was performed. In COS-7 cells, ESD could activate the transcription activity of PPAR γ in a dose-dependent manner and the maximal efficacy was achieved by 20 μM ESD, as shown in Fig. 3A. Western blot




Fig. 2 – Deoxyelephantopin (ESD) specifically binds to PPAR γ as investigated by SPR technology based Biacore 3000 instrument. The sensorgrams were obtained from injection of series of concentration of rosiglitazone over the immobilized PPAR γ -LBD (A); or ESD over the immobilized PPAR γ -LBD (B); PPAR α -LBD (C); PPAR δ -LBD (D); PPAR γ -LBD (S342G) (G) and PPAR γ -LBD (G284A) (H), and rosiglitazone over the immobilized PPAR γ -LBD (S342G) (E) and PPAR γ -LBD (G284A) (F).




Fig. 2. (Continued).

analysis showed that PPAR γ is highly expressed in HGC, HeLa and A549 cells (Supplementary Fig. S3), and ESD could also increase the PPAR γ transcription activity in these three cancer cells (Fig. 3D). Moreover, a significant enhancement of PPAR γ transcription activity was observed when increasing concentrations of ESD were added to a non-saturating concentration of rosiglitazone (Fig. 3B and D).

To further determine whether ESD activated PPAR γ via its ligand-binding domain, we fused PPAR γ -LBD with Gal4DNA-binding domain and tested the effect of ESD on this chimeric protein. As indicated in Fig. 3C, ESD could transactivate Gal4-PPAR γ -LBD with a comparable efficacy as it activates full-length PPAR γ , and also significantly enhance the rosiglitazone's agonistic effect on PPAR γ -LBD. These results thus implied that ESD exhibited less potent transactivation activity than rosiglitazone.

3.3. Molecular modeling of PPAR γ -LBD/ESD binding

Since we have found that ESD could increase PPAR γ transactivation by functioning as a selective PPAR γ ligand, to further investigate PPAR γ -LBD/ESD interaction at atomic level, molecular docking analysis was employed. During the assay, ESD was docked into the ligand-binding site of PPAR γ -LBD with the program AutoDock 3.0.5 [19]. The top pose, ranked by the "estimated free energy of binding", was

chosen as the predicted binding mode of ESD. As shown in Fig. 4A, ESD bound in the hydrophobic part of ligand-binding pocket of PPAR γ -LBD. Twenty-one hydrophobic interaction atom pairs between the compound and the protein formed. Six atom pairs were contributed by the hydrophobic interaction between Gly284 and the large ring (C1, C2, C3, C4, C8, C10, C11, C12, C14 and C15) of ESD (Fig. 4C), which might anchor the compound in the pocket. The lack of side chain of Gly284 seemed to be very important for ESD binding (Fig. 4B), since the side chain would exert steric repulsive effect on this large ring of the compound. As indicated in Fig. 4C, ESD formed only one hydrogen bond with the side-chain oxygen (OG) of Ser342. Additional docking studies of the mutated PPAR γ -LBD (G284A and S342G) showed that the docked ESD could no longer be in the ligand-binding pocket of PPAR γ -LBD (data not shown). These results thereby indicated that residues Gly284 and Ser342 are essential for ESD binding to PPAR γ -LBD.

By structural alignment using Swiss-PdbViewer [23] of the three human PPAR isoforms, it is noteworthy to see that residues [Gly284, Ser342] in PPAR γ are substituted by [Cys275, Ala333] in PPAR α and [Arg284, Ala342] in PPAR δ . Obviously, the side chains of Cys275 in PPAR α and Arg284 in PPAR δ may exert steric repulsive effects on the large ring of ESD, while Ala333 in PPAR α and Ala342 in PPAR δ lack hydrogen-bond donor in their side chains. Therefore, such residue substitutions among




Fig. 3 – Effects of ESD on PPAR_γ transcription activity. Cos-7 cell was transiently co-transfected with hPPAR_γ/RXR_α/pSV-PPRE-Luc and incubated with different concentrations of ESD (A), or stimulated with a fixed amount of rosiglitazone (10⁻⁷ M) together with increasing concentrations of ESD (B), and activation of ESD on PPAR_γ-Gal4/UAS-E1b-TATA-Luc (C). HGC, A549 and HeLa cells were transiently co-transfected with hPPAR_γ/RXR_α/pSV-PPRE-Luc and incubated alone with 10 μM ESD or together with 1 μM rosiglitazone (D). Each point was performed in triplicate, and the figure is a representative of four independent experiments. **p* < 0.05 vs. control; ***p* < 0.01 vs. control; #*p* < 0.05 vs. rosiglitazone (ROS).

human PPAR subtypes have provided a good explanation for the binding selectivity of ESD against PPAR_γ.

In addition, the importance of residues Gly284 and Ser342 in PPAR_γ/ESD binding was further supported by SPR assay against the mutated PPAR_γ-LBD proteins (G284A and S342G). As shown in Fig. 2G and H, these two mutations abolished the binding of ESD to PPAR_γ, while rosiglitazone retained highly binding affinity to the mutants (Fig. 2E and F). These results thus confirmed the above-mentioned ESD/PPAR_γ-LBD interaction model, in which ESD adopted a distinct binding mode compared with rosiglitazone [24].

3.4. ESD inhibits proliferation of different cancer cells through PPAR_γ-independent pathway

Based on the recent reports that PPAR_γ has been developed as an essential target for exploring potential anti-cancer agents and PPAR_γ agonists exhibited anti-tumor activities both *in vitro* and *in vivo* [1,6], SRB based assay was thus applied to test the

inhibition of ESD against the proliferation of HGC, A549 and HeLa cancer cells in our work. As indicated in Fig. 5A–C, ESD exhibited high inhibition activities against the proliferation of A549, HeLa and HGC cells with IC₅₀ values of 4.2, 5.4 and 4.7 μM, respectively. Altogether, the results demonstrated the anti-tumor function of ESD in several different cancer cell lines.

To investigate whether the anti-proliferation effect of ESD on cancer cells could be mediated by PPAR_γ activation, HGC, A549 and HeLa cells were pretreated with or without the PPAR_γ specific antagonist GW9662 (20 μM) for 45 min before the addition of ESD (10 μM) for additional 24 h. Cell numbers were determined by SRB assay. As shown in Fig. 5D, ESD significantly decreased cell numbers and GW9662 (20 μM) itself had no detectable effect on cancer cell. The GW9662-pretreatment cancer cells failed to show the abrogation of the inhibitory effect of ESD on cell growth. Moreover, to further study the relationship between the anti-proliferation effect of ESD and PPAR_γ activation, siRNA technology based assay was




Fig. 4 – Modeled interaction of ESD with PPAR γ -LBD. Protein backbone of PPAR γ -LBD is shown as a ribbon model. Selected protein residues (Gly284 and Ser342) and ligands are shown as stick models. (A) Model structure of ESD is docked into a crystallographic structure of the PPAR γ -LBD

also carried out, in which HGC cell was transfected with pSuperbasic (as a control group) and PPAR γ siRNA plasmid that caused a decrease in PPAR γ protein level (Fig. 5E, inset). As indicated in Fig. 5E, in the PPAR γ knockdown HGC cell, the inhibition ability of ESD against the cell growth could not be repressed as compared with the control group (transfection with pSuperbasic). All these results thus implied that ESD could inhibit the proliferation of cancer cells possibly through a PPAR γ -independent pathway, although some further studies are required to explore the detailed mechanisms about ESD-mediated anticancer effect.


3.5. ESD arrested cell cycle at G₂/M phase and induced apoptosis in HeLa cancer cell

To further investigate the ESD-mediated tumor cell growth inhibition, we examined the DNA content and cell cycle distribution of ESD-treated cells by flow cytometry. The results showed that ESD could induce apoptosis and cell cycle arrest at G₂/M phase of HeLa cell in a dose-dependent manner (Fig. 6A). In detail, cell population in G₁ phase decreased from 58.40% in non-treated control cells to 26.12 and 17.15% in cells treated with 10 and 20 μ M of ESD, respectively; and G₂/M phase cells increased from 20.20% (control) to 63.50% (20 μ M). The apoptosis induced by ESD was examined by PARP cleavage assay [14] and caspase activation based investigation [25]. As shown in Fig. 6B, ESD could dose-dependently cleave the PARP protein, and the bands of caspase 3 and caspase 9 were decreased at 24 h with the addition of ESD in HeLa cell in a dose-dependent manner. These results thereby suggested that ESD could significantly induce apoptosis in HeLa cell.

4. Discussion

Deoxyelephantopin (ESD) is a sesquiterpene lactone isolated from *Elephantopus carolinianus* Willd plant that demonstrates anti-tumor, anti-inflammatory and invasion-inhibiting activities [26]. Recently, Ichikawa et al. [14] reported that ESD could inhibit both the NF- κ B activation and the NF- κ B-regulated gene expression by repressing IKK, which phosphorylates and degrades I- κ B subunit and induces nuclear translocation of p65 and p50 subunits. However, the direct target for ESD still remains unclear. In the present study, PPAR γ was determined as the potential target for ESD as investigated by SPR and transactivation assays. Molecular docking with site-directed mutagenesis investigation further suggested that different from the typical full agonist rosiglitazone, ESD adopts a distinct binding mode against PPAR γ , in which ESD failed to interact with residues His323 and His449 where rosiglitazone

(Protein Data Bank entry 2F4B); (B) close-up of the PPAR γ ligand binding pocket with ESD, and rosiglitazone (yellow, from PDB entry 2PRG, overlaid by superposition of protein backbone); (C) amino acid residues involved in the ESD binding, H-bond represented as dashed line, and spiked residue hydrophobic contacts with the ligand. (A) and (B) were generated with PyMOL and (C) was generated with LIGPLOT.



(D) *P<0.05 vs. cells with no treatment

(E) *P<0.05 vs. cells with no treatment

Fig. 5 – ESD inhibits proliferation of different cancer cells through PPAR_γ-independent pathway.

(A) A549, (B) HeLa and (C) HGC cells were seeded into a 96-well plate with 5000 cells per well and incubated at 37 °C for 24 h and then the cells were treated with increasing concentrations of ESD for another 72 h. Inset: the fitting IC₅₀ value of ESD against each cancer cell. (D) A549, HeLa and HGC cells were pretreated with or without GW9662 (20 μM) for 45 min before addition of ESD (10 μM) for another 24 h. *p < 0.05 vs. cells with no treatment. (E) HGC cell was transfected with PPAR_γ siRNA and pSuperbasic (control group) as indicated in “Section 2” and then the cells were treated with or without ESD (10 μM) for 24 h. Inset: the PPAR_γ protein level was decreased by transfected siRNA PPAR_γ in HGC cell. The cell numbers were measured by SRB assay as indicated in “Section 2”. Each point was performed in triplicate, and the figure is a representative of four independent experiments. *p < 0.05 vs. cells with no treatment.




Fig. 6 – Induction of cell cycle arrest and apoptosis in HeLa cancer cell by ESD. (A) Cells were incubated with increasing concentrations of ESD for 24 h, and then collected, fixed, stained with propidium iodide and analyzed for DNA content by flow cytometry. Percentages of cells in different phases of cell cycle: G1, G2, S and sub-G1 are indicated in each panel. The X-axis means DNA content, and the figure is a representative of four independent experiments. **(B)** HeLa cells were incubated with 10 μM ESD for 24 h. The cells were harvested and lysed in protein loading dye, subjected to SDS-PAGE, and blotted with an anti-PARP, anti-caspase 3, anti-caspase 9 antibodies.

usually binds [24]. Moreover, the results that ESD located at the entrance of the binding pocket of PPAR γ with only one hydrogen bond to Ser342 and failed to directly interact with AF-2 implicated that such ESD binding to PPAR γ is more of partial agonistic feature [27], similar to the binding cases for the partial PPAR γ agonists PA-082 [27], 2-BABA [28], nTZDpa [29] and AGP [30], in which the hydrogen bonding to AF-2 was not essential.

PPAR γ is regarded as a potential target for the discovery of anti-cancer agents and various of PPAR γ ligands have been discovered to exhibit anti-proliferation activities against a wide variety of cancer cells, although the detailed mechanisms still remain unclear [31]. Some studies demonstrated that PPAR γ activation could repress proinflammatory transcription factors such as AP-1, STAT and NF- κ B by PPAR γ -dependent pathway [32]. For this respect, three models for the cross-talk

between PPAR and NF- κ B have been reported: (1) PPAR might inhibit NF- κ B activation by inducing I κ B synthesis [33]; (2) PPAR γ might compete with NF- κ B for essential coactivators thus inhibiting NF- κ B activation through transrepression mechanisms [34,35] and (3) PPAR γ might be targeted to nuclear receptor corepressor (NCoR)–histone deacetylase-3 (HDAC3) complexes on NF- κ B gene promoters by SUMOylation in its ligand-binding domain [36]. However, several previous reports indicated that for some types of the PPAR γ ligands, their anti-cancer effects might be independent of PPAR γ activation. For example, 15d-PGJ₂ is a PPAR γ agonist and shows inhibition activity against cancer cell proliferation without subjecting to PPAR γ activation. It is reported that 15d-PGJ₂ could repress NF- κ B-related gene expression through covalent modification of critical cysteine residues in I- κ B kinase and prevented the nuclear translocation of NF- κ B [37]. In addition, some studies revealed that PPAR γ classical agonists TZDs (e.g. troglitazone) exhibit anti-cancer effects via a PPAR γ -independent pathway and some non-PPAR γ targets such as extracellular signal-regulated kinases, c-Jun N-terminal protein kinase, p38 and Bcl-2 members have been implicated [38,39]. In fact, the detailed PPAR γ -dependent or -independent anti-cancer mechanism study for PPAR γ ligands has become an alluring project [31]. In our work, we demonstrated that ESD is a PPAR γ partial agonist and exhibits anti-cancer effect possibly through a PPAR γ -independent pathway as investigated by siRNA and PPAR γ specific-inhibition based assays. As indicated above, there seems to be a big complexity concerning the anti-cancer characters for the PPAR γ ligands. By an unclear anti-cancer mechanism, ESD might function in a mode similar to the published PPAR γ partial agonist CDDO [7,40,41].

As has been investigated in this work, ESD exhibits potent anti-proliferation effects on several tumor cell lines, and the previous report indicated that ESD could repress NF- κ B activation by inhibiting I κ B α kinase (IKK) to disrupt the phosphorylation and degradation of the I κ B α subunit and subsequent nuclear translocation of p65 subunit [14]. Therefore, with all these facts in mind, we proposed that ESD might take a PPAR γ -NF- κ B mediated pathway for performing its anti-cancer activity, although further studies are required for confirmation of this ESD-mediated PPAR γ -I κ B-NF- κ B network.

Recently, the studies have indicated that PPAR γ activation correlated with the inhibition against the proliferation of cancer cells by inducing cell cycle arrest at G0/G1 phase, although the exact mechanism of PPAR γ in controlling cell cycle remains incompletely understood [42]. In our work, we also investigated that rosiglitazone induced cell cycle arrest at G0/G1 phase in HeLa cell (Supplementary Fig. S4), compared with the arresting at G2/M phase by ESD. Interestingly, Fajas et al. [43] recently reported that PPAR γ activation caused cell cycle arrest at G0/G1 phase in the presence of retinoblastoma protein (RB), whereas resulted in accumulating in G2/M in the absence of RB. Moreover, PPAR γ ligands 15d-PGJ₂ and troglitazone induced cholangiocarcinoma cell cycle arrest at G2/M through p53-dependent GADD45 and p21^{WAF1/Cip1} pathway [44]. Similar to the case for the known PPAR γ partial agonist CDDO [7], ESD could also inhibit cell proliferation by inducing G2/M cell cycle arrest in cancer cells. Therefore, our

work might possibly provide further insight into the cell cycle analysis caused by the partial agonist induced PPAR γ activation in tumor cells.

Together with the previously published results [14], we expected that our work might help facilitate in providing novel insight into the underlying anti-tumor mechanism for ESD. The multifunctional characters of ESD, including PPAR γ activation, NF- κ B inhibition, anti-proliferation effect and apoptosis induction in tumor cells have made ESD a potential lead compound for further research.

Acknowledgments

We thank Prof. J. L. Jameson for Gal4-PPAR γ -LBD plasmid and UAS-E1b-TATA-Luc reporter gene. This work was supported by the State Key Program of Basic Research of China (grants 2004CB58905, 2006AA09Z447, 2007CB914304), the National Natural Science Foundation of China (grants 30525024, 90713046 and 20721003), Shanghai Basic Research Project from the Shanghai Science and Technology Commission (grants 06JC14080, 03DZ19228) and Foundation of Chinese Academy of Sciences (grant KSCX1-YW-R-18).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at [doi:10.1016/j.bcp.2007.11.021](https://doi.org/10.1016/j.bcp.2007.11.021).

REFERENCES

- [1] Tenenbaum A, Fisman EZ, Motro M. Metabolic syndrome and type 2 diabetes mellitus: focus on peroxisome proliferator activated receptors (PPAR). *Cardiovasc Diabetol* 2003;2:4.
- [2] Sarraf P, Mueller E, Smith WM, Wright HM, Kum JB, Aaltonen LA, et al. Loss-of-function mutations in PPAR gamma associated with human colon cancer. *Mol Cell* 1999;3:799–804.
- [3] Tontonoz P, Singer S, Forman BM, Sarraf P, Fletcher JA, Fletcher CD, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. *Proc Natl Acad Sci USA* 1997;94:237–41.
- [4] Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, et al. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. *Nat Med* 1998;4:1046–52.
- [5] Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, et al. Terminal differentiation of human breast cancer through PPAR gamma. *Mol Cell* 1998;1:465–70.
- [6] Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, et al. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. *Proc Natl Acad Sci USA* 1998;95:8806–11.
- [7] Lapillonne H, Konopleva M, Tsao T, Gold D, McQueen T, Sutherland RL, et al. Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces

- growth arrest and apoptosis in breast cancer cells. *Cancer Res* 2003;63:5926–39.
- [8] Suh N, Wang Y, Williams CR, Risingsong R, Gilmer T, Willson TM, et al. A new ligand for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), GW7845, inhibits rat mammary carcinogenesis. *Cancer Res* 1999;59:5671–3.
- [9] Reginato MJ, Bailey ST, Krakow SL, Minami C, Ishii S, Tanaka H, et al. A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptor gamma-activating properties. *J Biol Chem* 1998;273:32679–84.
- [10] Kumagai T, Ikezoe T, Gui D, O'Kelly J, Tong XJ, Cohen FJ, et al. RWJ-241947 (MCC-555), a unique peroxisome proliferator-activated receptor-gamma ligand with antitumor activity against human prostate cancer in vitro and in beige/nude/X-linked immunodeficient mice and enhancement of apoptosis in myeloma cells induced by arsenic trioxide. *Clin Cancer Res* 2004;10:1508–20.
- [11] Han S, Wada RK, Sidell N. Differentiation of human neuroblastoma by phenylacetate is mediated by peroxisome proliferator-activated receptor gamma. *Cancer Res* 2001;61:3998–4002.
- [12] Masuda T, Wada K, Nakajima A, Okura M, Kudo C, Kadowaki T, et al. Critical role of peroxisome proliferator-activated receptor gamma on anoikis and invasion of squamous cell carcinoma. *Clin Cancer Res* 2005;11:4012–21.
- [13] Schaefer KL, Wada K, Takahashi H, Matsuhashi N, Ohnishi S, Wolfe MM, et al. Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells. *Cancer Res* 2005;65:2251–9.
- [14] Ichikawa H, Nair MS, Takada Y, Sheeja DB, Kumar MA, Oommen OV, et al. Isodeoxyelephantopin, a novel sesquiterpene lactone, potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis through suppression of nuclear factor-kappaB (nf-kappaB) activation and nf-kappaB-regulated gene expression. *Clin Cancer Res* 2006;12:5910–8.
- [15] Kim J, Yang P, Suraokar M, Sabichi AL, Llansa ND, Mendoza G, et al. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products. *Cancer Res* 2005;65:6189–98.
- [16] Ye F, Zhang ZS, Luo HB, Shen JH, Chen KX, Shen X, et al. The dipeptide H-Trp-Glu-OH shows highly antagonistic activity against PPARgamma: bioassay with molecular modeling simulation. *Chembiochem* 2006;7:74–82.
- [17] Shenai BR, Sijwali PS, Singh A, Rosenthal PJ. Characterization of native and recombinant falcipain-2, a principal trophozoite cysteine protease and essential hemoglobinase of *Plasmodium falciparum*. *J Biol Chem* 2000;275:29000–1.
- [18] Mahindroo N, Wang CC, Liao CC, Huang CF, Lu IL, Lien TW, et al. Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies. *J Med Chem* 2006;49:1212–6.
- [19] Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, et al. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. *J Comput Chem* 1998;19(14):1639–62.
- [20] Misra P, Chakrabarti R, Vikramadithyan RK, Bolusu G, Juluri S, Hiriyan J, et al. PAT5A: a partial agonist of peroxisome proliferator-activated receptor gamma is a potent antidiabetic thiazolidinedione yet weakly adipogenic. *J Pharmacol Exp Ther* 2003;306:763–71.
- [21] Park Y, Freedman BD, Lee EJ, Park S, Jameson JL. A dominant negative PPARgamma mutant shows altered cofactor recruitment and inhibits adipogenesis in 3T3-L1 cells. *Diabetologia* 2003;46:365–77.
- [22] Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, et al. New colorimetric cytotoxicity assay for anticancer-drug screening. *J Natl Cancer Inst* 1990;82:1107–12.
- [23] Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. *Electrophoresis* 1997;18:2714–23.
- [24] Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, et al. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. *Nature* 1998;395:137–43.
- [25] Hengartner MO. The biochemistry of apoptosis. *Nature* 2000;407:770–6.
- [26] Lee KH, Cowherd CM, Wolo MT. Antitumor agents. XV: Deoxyelephantopin, an antitumor principle from *Elephantopus carolinianus* Willd. *J Pharm Sci* 1975;64:1572–3.
- [27] Burgermeister E, Schnoebelen A, Flament A, Benz J, Stihle M, Gsell B, et al. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. *Mol Endocrinol* 2006;20:809–30.
- [28] Ostberg T, Svensson S, Selen G, Uppenberg J, Thor M, Sundbom M, et al. A new class of peroxisome proliferator-activated receptor agonists with a novel binding epitope shows antidiabetic effects. *J Biol Chem* 2004;279:41124–30.
- [29] Berger JP, Petro AE, Macnaul KL, Kelly LJ, Zhang BB, Richards K, et al. Distinct properties and advantages of a novel peroxisome proliferator-activated protein [gamma] selective modulator. *Mol Endocrinol* 2003;17:662–76.
- [30] Tsukahara T, Tsukahara R, Yasuda S, Makarova N, Valentine WJ, Allison P, et al. Different residues mediate recognition of 1-O-oleylsophosphatidic acid and rosiglitazone in the ligand binding domain of peroxisome proliferator-activated receptor gamma. *J Biol Chem* 2006;281:3398–407.
- [31] Koeffler HP. Peroxisome proliferator-activated receptor gamma and cancers. *Clin Cancer Res* 2003;9:1–9.
- [32] Pascual G, Glass CK. Nuclear receptors versus inflammation: mechanisms of transrepression. *Trends Endocrinol Metab* 2006;17:321–7.
- [33] Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. *Circ Res* 1999;85:394–402.
- [34] Kamei Y, Xu L, Heinzel T, Torchia J, Kurokawa R, Glass B, et al. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. *Cell* 1996;85:403–14.
- [35] Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, et al. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. *J Biol Chem* 1998;273:29291–4.
- [36] Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. *Nature* 2005;437:759–63.
- [37] Straus DS, Pascual G, Li M, Welch JS, Ricote M, Hsiang CH, et al. 15-Deoxy-delta 12,14-prostaglandin J2 inhibits multiple steps in the NF-kappa B signaling pathway. *Proc Natl Acad Sci USA* 2000;97:4844–9.
- [38] Gouni-Berthold I, Berthold HK, Weber AA, Ko Y, Seul C, Vetter H, et al. Troglitazone and rosiglitazone induce apoptosis of vascular smooth muscle cells through an

- extracellular signal-regulated kinase-independent pathway. *Naunyn Schmiedebergs Arch Pharmacol* 2001;363:215-21.
- [39] Weng JR, Chen CY, Pinzone JJ, Ringel MD, Chen CS. Beyond peroxisome proliferator-activated receptor gamma signaling: the multi-facets of the antitumor effect of thiazolidinediones. *Endocr Relat Cancer* 2006;13:401-13.
- [40] Chintharlapalli S, Papineni S, Konopleva M, Andreef M, Samudio I, Safe S. 2-Cyano-3,12-dioxoolean-1,9-dien-28-oic acid and related compounds inhibit growth of colon cancer cells through peroxisome proliferator-activated receptor gamma-dependent and -independent pathways. *Mol Pharmacol* 2005;68:119-28.
- [41] Shishodia S, Sethi G, Konopleva M, Andreeff M, Aggarwal BB. A synthetic triterpenoid, CDDO-Me, inhibits I κ B α kinase and enhances apoptosis induced by TNF and chemotherapeutic agents through down-regulation of expression of nuclear factor kappaB-regulated gene products in human leukemic cells. *Clin Cancer Res* 2006;12:1828-38.
- [42] Fajas L, Debril MB, Auwerx J. Peroxisome proliferator-activated receptor-gamma: from adipogenesis to carcinogenesis. *J Mol Endocrinol* 2001;27:1-9.
- [43] Fajas L, Egler V, Reiter R, Miard S, Lefebvre AM, Auwerx J. PPARgamma controls cell proliferation and apoptosis in an RB-dependent manner. *Oncogene* 2003;22:4186-93.
- [44] Han C, Demetris AJ, Michalopoulos GK, Zhan Q, Shelhamer JH, Wu T. PPARgamma ligands inhibit cholangiocarcinoma cell growth through p53-dependent GADD45 and p21 pathway. *Hepatology* 2003;38:167-77.